A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent

Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second leading cause of cancer mortality by 2030. PDAC remains resistant to the majority of systemic chemotherapies. In this paper, we explore if epigenetic sensitization can improve chemotherapy response in PDAC. Multiple PDAC cell lines were tested with serial concentrations of the epigenetic modulators 5-azacitidine (Aza) and guadecitabine (SGI-110). Guadecitabine was effective at inhibiting the expression of DNA Methyltransferase 1 (DNMT1) and in decreasing cell viability at nanomolar concentrations. We also report that guadecitabine has increased efficacy following a delay period or as we reference, a ‘rest period’. Sensitization with guadecitabine improved response to the chemotherapeutic agent–Irinotecan- as measured by decreased cell viability and accompanied by an increase in caspase activity. Additional studies are needed to understand the mechanism of action.

[1]  C. Zahnow,et al.  Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma , 2018, Oncotarget.

[2]  E. Rock,et al.  Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. , 2017, The Lancet. Oncology.

[3]  C. Zahnow,et al.  Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells , 2017, PloS one.

[4]  Wei Wang,et al.  Critical threshold levels of DNA methyltransferase 1 are required to maintain DNA methylation across the genome in human cancer cells. , 2017, Genome research.

[5]  A. Ray,et al.  A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors , 2016, Oncotarget.

[6]  A. Ray,et al.  A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. , 2017, Oncotarget.

[7]  S. Baylin,et al.  Abstract CT017: A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients , 2016 .

[8]  Nita Ahuja,et al.  Epigenetic Therapeutics: A New Weapon in the War Against Cancer. , 2016, Annual review of medicine.

[9]  H. Zhang,et al.  Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK , 2016, Oncology reports.

[10]  R. Day,et al.  Episensitization: Defying Time’s Arrow , 2015, Front. Oncol..

[11]  J. Iovanna,et al.  A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor , 2014, Oncotarget.

[12]  D. Matei,et al.  The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer , 2014, Clinical Cancer Research.

[13]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[14]  J. Herman,et al.  Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer , 2014, Clinical Cancer Research.

[15]  S. Anant,et al.  DNA Methyltransferases: A Novel Target for Prevention and Therapy , 2013, Front. Oncol..

[16]  X. Wang,et al.  Effect of inhibition of MEK pathway on 5-aza-deoxycytidine-suppressed pancreatic cancer cell proliferation. , 2013, Genetics and molecular research : GMR.

[17]  Jian-ming Zheng,et al.  Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression , 2013, Journal of experimental & clinical cancer research : CR.

[18]  J. Herman,et al.  Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer , 2013, Clinical Cancer Research.

[19]  T. Clozel,et al.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. , 2013, Cancer discovery.

[20]  B. Tycko,et al.  Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. , 2013, Cancer research.

[21]  F. Chan,et al.  Detection of necrosis by release of lactate dehydrogenase activity. , 2013, Methods in molecular biology.

[22]  M. Maio,et al.  Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide , 2013, Cancer Immunology, Immunotherapy.

[23]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[24]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[25]  Martin J. Aryee,et al.  A DNA hypermethylation module for the stem/progenitor cell signature of cancer , 2011, Genome research.

[26]  E. Zabarovsky,et al.  Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors , 2011, Cell adhesion & migration.

[27]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[28]  R. Bast,et al.  Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer , 2011, Cancer.

[29]  Jide Wang,et al.  Promoter hypermethylation and histone hypoacetylation contribute to pancreatic-duodenal homeobox 1 silencing in gastric cancer. , 2010, Carcinogenesis.

[30]  Herb Chen,et al.  Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. , 2010, International journal of clinical and experimental medicine.

[31]  Seung‐Mo Hong,et al.  Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors , 2010, Cancer biology & therapy.

[32]  D. Matei,et al.  Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. , 2010, Gynecologic oncology.

[33]  A. Jimeno,et al.  Characterizing DNA methylation patterns in pancreatic cancer genome , 2009, Molecular oncology.

[34]  J. Herman,et al.  Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. , 2008, Cancer research.

[35]  F. Lyko,et al.  Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.

[36]  M. Chatterjee,et al.  Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. , 2007, Journal of medical microbiology.

[37]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[38]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[39]  A. Scarpa,et al.  Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway , 2005, Oncogene.

[40]  L. Silverman.  DNA methyltransferase inhibitors in myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[41]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[42]  R. Hruban,et al.  Missense Mutations of MADH4 , 2004, Clinical Cancer Research.

[43]  J. Cameron,et al.  p16 Inactivation in Pancreatic Intraepithelial Neoplasias (PanINs) Arising in Patients With Chronic Pancreatitis , 2003, The American journal of surgical pathology.

[44]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[45]  R J Roberts,et al.  Recombinant Human DNA (Cytosine-5) Methyltransferase , 1999, The Journal of Biological Chemistry.

[46]  R J Roberts,et al.  Recombinant Human DNA (Cytosine-5) Methyltransferase , 1999, The Journal of Biological Chemistry.

[47]  C. Moskaluk,et al.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.

[48]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[49]  R. Hruban,et al.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.

[50]  S. Hirohashi,et al.  Pancreatic adenocarcinomas frequently show p53 gene mutations. , 1993, The American journal of pathology.

[51]  H. Pinedo,et al.  Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. , 1986, Cancer research.

[52]  B. Chabner,et al.  Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. , 1973, Biochemical pharmacology.